
LEO Pharma has closed its acquisition of dersimelagon from Tanabe Pharma after the FDA accepted the drug's NDA for filing and granted Priority Review, with a PDUFA date expected by the end of February 2027.
A glimpse at what to expect from Dermatology Times this week.
Some of the content the staff at Dermatology Times will be publishing this week includes:
New articles from our June issue;
Engaging polls;
Content from our upcoming July issue;
The latest FDA pipeline updates;
Plus more!






